The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg

被引：0

作者：

Bocci, A. ^{[1
]}

Spielniann, D. ^{[1
]}

Azzini, Pr ^{[1
]}

Guaschino, Pr ^{[1
]}

Affronti, G. ^{[1
]}

Villani, Pr ^{[1
]}

Boselli, Pr ^{[1
]}

Genazzani, Pr ^{[1
]}

Flamigni, Z. C. ^{[1
]}

Omodei, U. ^{[1
]}

Bolis, P. ^{[1
]}

Marsoni, V. ^{[1
]}

Luerti, M. ^{[1
]}

Simenel, J. L. ^{[1
]}

Ouvry-Neveu, B. ^{[1
]}

Andre, G. ^{[1
]}

David, S. ^{[1
]}

Durand, J. L. ^{[1
]}

Ehret-Mentre, C. ^{[1
]}

Gensburger, J. M. ^{[1
]}

Goetzmann, P. ^{[1
]}

Jung-Faerber, S. ^{[1
]}

Keller, D. ^{[1
]}

Lempereur, M. ^{[1
]}

Plumere, C. ^{[1
]}

Spielmann, A. ^{[1
]}

Katz, J. L. ^{[1
]}

Sebaoun, J. ^{[1
]}

Belaisch, J. ^{[1
]}

Hammer, F. ^{[1
]}

Salama, B. ^{[1
]}

Aissaoui, S. ^{[1
]}

Taube, A. M. ^{[1
]}

Nakache, H. ^{[1
]}

Soria, J. ^{[1
]}

Joffo, M. ^{[1
]}

Lardenois, H. ^{[1
]}

Leclerc, P. ^{[1
]}

Ponsar, C. ^{[1
]}

Saubry-Bobet, V. ^{[1
]}

Blaiset, E. ^{[1
]}

Veyres, F. ^{[1
]}

Clamp, M. ^{[1
]}

Menon, K. V. K. ^{[1
]}

Moran, D. G. ^{[1
]}

Randall, S. ^{[1
]}

Shaw, P. J. ^{[1
]}

Bruni, V. ^{[1
]}

Massobrio, M. ^{[1
]}

Crosignani, P. ^{[1
]}

机构：

[1] Wyeth Ayersr Res, F-92031 Paris, France

来源：

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE | 1999年 / 4卷

关键词：

Oral contraceptive; Contraceptive efficacy; Gestodene; Ethinylestradiol;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective The safety and contraceptive efficacy of a new 24-day regimen of an oral contraceptive combination containing gestodene (GTD) 60 mu g and ethinylestradiol (EE) 15 mu g was evaluated in an open-label, multicenter study. Methods Adult women received GTD 60 mu g/EE 15 mu g from day 1 to 24 and 4 days of placebo during a 28-day cycle for either 13 or 19 cycles. Results Of the 1515 subjects enrolled, 1496 were included in the intent-to-treat analysis. A total of three pregnancies were reported during the 18 194 treatment cycles of the study, yielding a Pearl index of 0.21. Life-table analysis, based on 16 954 cycles, gave an accidental pregnancy rate of 0.0033. The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%). The most frequent reasons for withdrawal from the study were metrorrhagia, flu syndrome and absence of bleeding. Analyses of withdrawal and intermenstrual bleeding and spotting indicated acceptable cycle control. Conclusions The 24-day GTD 60 mu g/EE 15 mu g, regimen appears to be a well-tolerated and effective method for low-dose oral contraception. The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy.

引用

页码：9 / 15

页数：7

共 50 条

[31] International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg
Boerrigter, PJ
Ellman, H
Dolker, M
CLINICAL THERAPEUTICS, 1999, 21 (01) : 118 - 127
[32] Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone
Endrikat, J
Hite, R
Bannemerschult, R
Gerlinger, C
Schmidt, W
CONTRACEPTION, 2001, 64 (01) : 3 - 10
[33] PHARMACOKINETICS AND PROTEIN-BINDING OF GESTODENE UNDER TREATMENT WITH A LOW-DOSE COMBINATION ORAL-CONTRACEPTIVE FOR 3 MONTHS
DIBBELT, L
KNUPPEN, R
KUHNZ, W
JUTTING, G
ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1992, 42-2 (09): : 1146 - 1152
[34] Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles
Rabe, Thomas
Hartschuh, Elena
Wahlstrom, Torsten
Hoeschen, Kornelia
Koenig, Simone
CONTRACEPTION, 2010, 82 (04) : 358 - 365
[35] Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies
Anttila, Leena
Bachmann, Gloria
Hernadi, Laszlo
Kunz, Michael
Marr, Joachim
Klipping, Christine
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 155 (02) : 180 - 182
[36] A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel
Jespersen, J
Endrikat, J
Düsterberg, B
Schmidt, W
Gerlinger, C
Wessel, J
Sidelmann, JJ
Skouby, SO
CONTRACEPTION, 2005, 72 (02) : 98 - 104
[37] A new low-dose monophasic combination oral contraceptive (Alesse(TM)) with levonorgestrel 100 mu g and ethinyl estradiol 20 mu g
Archer, DF
Maheux, R
DelConte, A
OBrien, FB
Adams, D
Appel, T
Brown, D
Carr, B
Chenault, B
Connell, E
Davila, G
Donovan, S
Faguant, R
Glick, H
Grimes, D
Hanson, M
Harris, JW
Hume, J
Kasparian, S
Katz, D
Lifson, MS
Mercer, L
Merritt, D
Moore, D
Schade, G
Spellacy, W
Stephenson, CD
Stewart, SK
Thorp, JM
Varner, E
Wallach, E
Blanchet, P
Boroditsky, R
Choquette, P
Guilbert, E
Lefebvre, Y
Powell, MG
Ross, S
Senikas, V
Young, R
Yuzpe, A
CONTRACEPTION, 1997, 55 (03) : 139 - 144
[38] Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive
Hendrix, SL
Alexander, NJ
CONTRACEPTION, 2002, 66 (06) : 393 - 399
[39] Yasminelle (R) : a new low-dose combined oral contraceptive containing drospirenone
Sillem, Martin
WOMENS HEALTH, 2006, 2 (04) : 551 - 559
[40] A comparative clinical investigation of two low-dose oral contraceptives containing either 75 μg gestodene or 150 μg desogestrel combined with 20 μg ethinylestradiol:: effect on hemostasis, lipid metabolism and carbohydrate metabolism
Bloemenkamp, KWM
Helmerhorst, FM
Dersjant-Roorda, MD
de Boer, R
Meyer, P
Spielmann, D
Kluft, C
GYNECOLOGICAL ENDOCRINOLOGY, 1998, 12 : 21 - 30

← 1 2 3 4 5 →